Nukkleus Inc. (NASDAQ:NUKK - Get Free Report) was the target of a large growth in short interest in February. As of February 28th, there was short interest totalling 280,800 shares, a growth of 54.5% from the February 13th total of 181,800 shares. Approximately 6.9% of the company's stock are sold short. Based on an average daily volume of 4,510,000 shares, the days-to-cover ratio is currently 0.1 days.
Nukkleus Stock Performance
Shares of NUKK stock traded up $1.02 on Wednesday, reaching $15.51. 89,972 shares of the stock were exchanged, compared to its average volume of 1,359,763. The business's 50 day moving average price is $19.15 and its 200 day moving average price is $11.83. Nukkleus has a twelve month low of $1.30 and a twelve month high of $78.32.
Nukkleus Company Profile
(
Get Free Report)
Nukkleus Inc, a financial technology company, provides blockchain-enabled technology solutions worldwide. It focuses on providing software and technology solutions for retail foreign exchange trading industry. The company provides transactions platform for dealing and risk management services. It also offers cross-border payment and transactions solutions and blockchain-enabled financial services solutions to institutional investors.
Featured Stories
Before you consider Nukkleus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nukkleus wasn't on the list.
While Nukkleus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.